Treatment Outcome and Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma (TNM Stage IVa) according to Anticancer drugs of Transhepatic Arterial Chemoinfusion.
- Author:
Sang Hoon AHN
1
;
Kwang Hyub HAN
;
Young Hoon YOUN
;
Myoung Hwan KIM
;
Kun Hoon SONG
;
Kwan Sik LEE
;
Chae Yoon CHON
;
Young Myoung MOON
;
Do Yun LEE
;
Jong Tae LEE
Author Information
1. Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Neoplasm/Liver/Hepatocellular carcinoma;
Treatment outcome;
Prognostic factors;
Intraarterial infusion;
Neoplasm staging
- MeSH:
Alkaline Phosphatase;
Bilirubin;
Carcinoma, Hepatocellular*;
Classification;
Humans;
Infusions, Intra-Arterial;
Neoplasm Staging;
Portal Vein;
Psychotherapy, Group;
Survival Rate;
Treatment Outcome*
- From:The Korean Journal of Hepatology
2000;6(4):456-467
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The study proposed to evaluate the efficacy of anticancer drugs of intraarterial chemoinfusion and investigate prognostic factors influencing survival. METHODS: A total of 127 patients diagnosed as having advanced hepatocellular carcinoma(HCC) of same stage (TNM stage IVa) from 1996 to 1998 were examined. Two intraarterial infusion chemotherapeutic regimens were employed: Adriamycin(Group I) and Cisplatin(Group II). RESULTS: Overall survival was significantly diffrent(10.0 vs 5.7months) and favored Group I. By the univariate analysis, significant prognostic factors included: age, portal vein thrombosis(PVT), size(>5cm) and type of tumor, response rate (size & -fetoprotein) at 3 months after therapy, level of albumin, alkaline phosphatase, and total bilirubin. After repeated therapy, Group I showed better survival (14.0 vs 7.9 months), but there was no statistical difference in survival rate between two groups in the case of large size, PVT, and diffuse type. CONCLUSION: Group I showed better survival than Group II in advanced HCC of TNM stage IVa. But, considering prognostic factors, there was no significant difference in survival rate between two groups except small size or nodular type of HCC. TNM classification of stage IVa should be reconsidered to include prognostic factors influencing survival rate such as PVT, size and type of HCC.
